Market open
Zenas BioPharma, Inc./$ZBIO
Zenas BioPharma shares are trading higher after the company reported its Q1 results.
3 minutes ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Zenas BioPharma, Inc.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
Ticker
$ZBIO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
130
ISIN
US98937L1052
Website
ZBIO Metrics
BasicAdvanced
$407M
-
-$7.00
-
-
Price and volume
Market cap
$407M
52-week high
$12.41
52-week low
$6.11
Average daily volume
191K
Financial strength
Total debt to equity
0.321
Management effectiveness
Valuation
Price to revenue (TTM)
15.104
Price to book
1.3
Price to tangible book (TTM)
1.3
Growth
Revenue change (TTM)
-70.00%
Earnings per share change (TTM)
-76.46%
ZBIO News
AllArticlesVideos
Investors Urged to Contact Levi & Korsinsky for Information Before June 16, 2025 - Zenas BioPharma, Inc. (ZBIO)
Accesswire·59 minutes ago
ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors - Lead Plaintiff Deadline June 16, 2025
Accesswire·3 hours ago
ZBIO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Zenas BioPharma, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!
Accesswire·3 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Zenas BioPharma, Inc. stock?
Zenas BioPharma, Inc. (ZBIO) has a market cap of $407M as of May 16, 2025.
What is the P/E ratio for Zenas BioPharma, Inc. stock?
The price to earnings (P/E) ratio for Zenas BioPharma, Inc. (ZBIO) stock is 0 as of May 16, 2025.
Does Zenas BioPharma, Inc. stock pay dividends?
No, Zenas BioPharma, Inc. (ZBIO) stock does not pay dividends to its shareholders as of May 16, 2025.
When is the next Zenas BioPharma, Inc. dividend payment date?
Zenas BioPharma, Inc. (ZBIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Zenas BioPharma, Inc.?
Zenas BioPharma, Inc. (ZBIO) does not currently have a Beta indicator.